Navidea Biopharmaceuticals (NAVB +4.7%) trades up today after reporting results of its 2013...

|About: Navidea Biopharmaceuticals (NAVB)|By:, SA News Editor

Navidea Biopharmaceuticals (NAVB +4.7%) trades up today after reporting results of its 2013 Annual Meeting of Stockholders held earlier today. NAVB made a series of presentations to shareholders highlighting Lymphoseek's U.S commercialization and indication expansion development activities, selection of a specialty pharma partner for its commercialization in Europe, and initiation of a pivotal NAV4694 Phase 3 registration study.